Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. 1997

D P Lookingbill, and D K Chalker, and J S Lindholm, and H I Katz, and S E Kempers, and C J Huerter, and J M Swinehart, and D J Schelling, and H C Klauda
Department of Medicine, Pennsylvania State University College of Medicine, Hershey, USA.

BACKGROUND It has previously been shown that a combination of erythromycin and benzoyl peroxide is superior to either ingredient when used alone in the treatment of acne. A clindamycin/benzoyl peroxide combination gel might have an advantage over erythromycin/benzoyl peroxide gel because the former does not require refrigeration after it is dispensed. OBJECTIVE Our purpose was to determine the efficacy and safety of a combination clindamycin/benzoyl peroxide gel when compared with benzoyl peroxide, clindamycin, or vehicle gels. METHODS In two double-blind, randomized, parallel, vehicle-controlled trials, patients were treated for 11 weeks with once-nightly application of one of the above preparations. Evaluations were performed at 2, 5, 8, and 11 weeks and included lesion counts and assessment of global responses and irritant effects. RESULTS A total of 334 patients completed the study. All three active preparations were significantly superior to the vehicle in global improvement and in reducing inflammatory lesions and noninflammatory lesions. The combination gel was significantly superior to the two individual agents in global improvement and reduction of inflammatory lesions and also to the clindamycin gel in reducing noninflammatory lesions. There was no significant difference in tolerance to the active gels versus the vehicle gel. CONCLUSIONS In the treatment of acne, topical clindamycin/benzoyl peroxide combination gel is well tolerated and superior to either individual ingredient.

UI MeSH Term Description Entries
D007509 Irritants Drugs that act locally on cutaneous or mucosal surfaces to produce inflammation; those that cause redness due to hyperemia are rubefacients; those that raise blisters are vesicants and those that penetrate sebaceous glands and cause abscesses are pustulants; tear gases and mustard gases are also irritants. Counterirritant,Counterirritants,Irritant,Pustulant,Pustulants,Rubefacient,Rubefacients,Vesicant,Vesicants
D007641 Keratolytic Agents Agents that soften, separate, and cause desquamation of the cornified epithelium or horny layer of skin. They are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases. Desquamating Agents,Skin-Peeling Agents,Agents, Desquamating,Agents, Keratolytic,Agents, Skin-Peeling,Skin Peeling Agents
D008297 Male Males
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002981 Clindamycin An antibacterial agent that is a semisynthetic analog of LINCOMYCIN. 7-Chloro-7-deoxylincomycin,Chlolincocin,Chlorlincocin,Cleocin,Clindamycin Hydrochloride,Clindamycin Monohydrochloride,Clindamycin Monohydrochloride, Monohydrate,Dalacin C,7 Chloro 7 deoxylincomycin,Hydrochloride, Clindamycin,Monohydrate Clindamycin Monohydrochloride,Monohydrochloride, Clindamycin,Monohydrochloride, Monohydrate Clindamycin
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness

Related Publications

D P Lookingbill, and D K Chalker, and J S Lindholm, and H I Katz, and S E Kempers, and C J Huerter, and J M Swinehart, and D J Schelling, and H C Klauda
February 2001, Cutis,
D P Lookingbill, and D K Chalker, and J S Lindholm, and H I Katz, and S E Kempers, and C J Huerter, and J M Swinehart, and D J Schelling, and H C Klauda
January 2001, American journal of clinical dermatology,
D P Lookingbill, and D K Chalker, and J S Lindholm, and H I Katz, and S E Kempers, and C J Huerter, and J M Swinehart, and D J Schelling, and H C Klauda
January 2001, Journal of cutaneous medicine and surgery,
D P Lookingbill, and D K Chalker, and J S Lindholm, and H I Katz, and S E Kempers, and C J Huerter, and J M Swinehart, and D J Schelling, and H C Klauda
July 2010, Journal of the American Academy of Dermatology,
D P Lookingbill, and D K Chalker, and J S Lindholm, and H I Katz, and S E Kempers, and C J Huerter, and J M Swinehart, and D J Schelling, and H C Klauda
February 2001, Cutis,
D P Lookingbill, and D K Chalker, and J S Lindholm, and H I Katz, and S E Kempers, and C J Huerter, and J M Swinehart, and D J Schelling, and H C Klauda
March 1996, International journal of dermatology,
D P Lookingbill, and D K Chalker, and J S Lindholm, and H I Katz, and S E Kempers, and C J Huerter, and J M Swinehart, and D J Schelling, and H C Klauda
January 1998, Indian journal of dermatology, venereology and leprology,
D P Lookingbill, and D K Chalker, and J S Lindholm, and H I Katz, and S E Kempers, and C J Huerter, and J M Swinehart, and D J Schelling, and H C Klauda
May 2012, The Journal of clinical and aesthetic dermatology,
D P Lookingbill, and D K Chalker, and J S Lindholm, and H I Katz, and S E Kempers, and C J Huerter, and J M Swinehart, and D J Schelling, and H C Klauda
December 2011, Journal of drugs in dermatology : JDD,
D P Lookingbill, and D K Chalker, and J S Lindholm, and H I Katz, and S E Kempers, and C J Huerter, and J M Swinehart, and D J Schelling, and H C Klauda
November 2009, Cutis,
Copied contents to your clipboard!